Taken together, this study indicates that celecoxib suppresses de novo lipogenesis and alleviates hepatic steatosis by inactivating Akt/mTORC1 signalling and by suppressing its downstream lipogenic factors. The gene discussed is AKT1; the disease is fatty liver disease.